Skip to main content
Gloved hand administering Obsidio Conformable Embolic.

Obsidio™ Conformable Embolic


Obsidio Embolic Limited Market Evaluation (LME) report

Background – Obsidio received 510(k) clearance in July 2022 and Boston Scientific acquired Obsidio (formerly GEM/Gel Embolic Material) from Obsidio, Inc. in August 2022. Boston Scientific chose to launch Obsidio Embolic in the US through a limited market evaluation (LME) to obtain early user experience prior to moving into a full commercial launch.

Methods – 27 sites in the US were chosen for the LME. Post completion of each case, the commercial representatives were tasked with completion of a case report survey.

Technical Success – Technical success for a Obsidio Embolic case was defined as successful embolization of the target vasculature. In the LME, Obsidio Embolic was able to achieve embolization target in all cases and had a success rate of 100% (131/131 cases).

513 KB
Download LME report

Obsidio first-in-human clinical study: evaluation of Obsidio Embolic safety and performance

Overview – A single-center study* sought to evaluate the safety and performance of Obsidio Conformable Embolic (OCE) in patients requiring vascular embolization for hypervascular renal tumors.

Objectives – The study sought to demonstrate that Obsidio Embolic could be delivered safely, occludes the artery where deposited without migration, and does not lead to a change in standard blood tests.

Results – Obsidio Embolic achieved the absence of flow in the blood vessels of tumors, with embolization demonstrated to be durable without migration at Day 7.

1 MB
Download Obsidio paper
Medical scans showing arteries before and after with Obsidio, delivery achieving absence of flow in the blood vessel of tumor and no migration of Obsidio Embolic (Day 7).
document icon with purple arrow pointing up.

Submit your Obsidio case

* Obsidio Conformable Embolic performance testing